Corticotropin releasing factor (CRF) regulates physiological and behavioral responses to stress. Trauma in early life or adulthood is associated with increased CRF in the cerebrospinal fluid and heightened anxiety. Genetic variance in CRF receptors is linked to altered risk for stress disorders. Thus, both heritable differences and environmentally induced changes in CRF neurotransmission across the lifespan may modulate anxiety traits. To test the hypothesis that CRF hypersignaling is sufficient to modify anxiety-related phenotypes (avoidance, startle, and conditioned fear), we induced transient forebrain-specific overexpression of CRF (CRFOE) in mice (1) during development to model early-life stress, (2) in adulthood to model adult-onset stress, or (3) across the entire postnatal lifespan to model heritable increases in CRF signaling. The consequences of these manipulations on CRF peptide levels and behavioral responses were examined in adulthood. We found that transient CRFOE during development decreased startle habituation and prepulse inhibition, and increased avoidance (particularly in females) recapitulating the behavioral effects of lifetime CRFOE despite lower CRF peptide levels at testing. In contrast, CRFOE limited to adulthood reduced contextual fear learning in females and increased startle reactivity in males but did not change avoidance or startle plasticity. These findings suggest that forebrain CRFOE limited to development is sufficient to induce enduring alterations in startle plasticity and anxiety, while forebrain CRFOE during adulthood results in a different phenotype profile. These findings suggest that startle circuits are particularly sensitive to forebrain CRFOE, and that the impact of CRFOE may be dependent on the time of exposure.
INTRODUCTION
Corticotropin releasing factor (CRF) coordinates autonomic, endocrine, and behavioral responses to stress. Both acute activation and overexpression of CRF (CRFOE) across the lifetime increase anxiety-like responses while pharmacological blockade or genetic disruption of CRF receptor type 1 (CRFR1) results in decreased anxiety (Risbrough and Stein, 2006b; Stenzel-Poore et al, 1994; Timpl et al, 1998; Zorrilla and Koob, 2010) . CRF signaling in the forebrain is necessary for many CRF-and stress-induced anxiety-like behaviors (Kolber et al, 2010; Muller et al, 2003) . In addition, early stress exposure in animals induces long-term changes in the CRF system (Plotsky et al, 2005) . CRF concentrations are elevated in the cerebrospinal fluid of individuals with childhood trauma history and posttraumatic stress disorder (PTSD) (Baker et al, 1999; Bremner et al, 1997; Lee et al, 2005) , while CRFR1 gene polymorphisms modulate the outcome of traumatic events (Bradley et al, 2008) . However, these association studies explain neither the causal relationships nor the underlying mechanisms between CRF signaling and anxiety. Traumatic experience may induce long-term enhancement of CRF neurotransmission resulting in increased anxiety, but it is also possible that individuals with trait differences in CRF signaling are more susceptible to develop anxiety disorders. CRF hypersignaling during early-life stress is another possible trajectory to develop increased risk for anxiety in adulthood. Animal studies suggest that CRF hypersignaling produces biomarkers that mimic some of those described in anxiety disorders, including increased startle reactivity, reduced startle plasticity, altered HPA-axis sensitivity, and altered structure and activity of the hippocampus and the amygdala supporting the potential role of CRF in increased anxiety (Ivy et al, 2010; Rainnie et al, 2004; Risbrough and Stein, 2006b) .
In the present study, we induced CRFOE in a temporally controlled manner to compare the contribution of different time points of CRF hypersignaling in the genesis of phenotypes associated with anxiety disorders. To model the hypotheses described above, we induced transient CRFOE in the forebrain during development (CRFOE dev ), adulthood (CRFOE adult ) or along the whole postnatal lifespan (CRFOE life ). CRFOE dev aimed to model CRF hypersignaling during childhood (early-life stress; (Heim and Nemeroff, 2001; Lee et al, 2005) ), CRFOE life modeled lifelong CRF hypersignaling (genetic predispositions; (Bradley et al, 2008) ), and CRFOE adult modeled adult-onset CRF hypersignaling (eg, induced by traumatic stress in adulthood; (Baker et al, 1999; Bremner et al, 1997) ). The anatomical targeting of CRFOE was restricted to the forebrain in order to exclude direct HPA-axis changes. Commonly described symptom domains in anxiety disorders include avoidance, altered fear learning, and startle hyperreactivity. Thus the aim of this model comparison is to help elucidate what 'symptom domains' forebrain CRF hypersignaling is sufficient to produce and what time periods are sufficient for these changes, providing a better understanding of phenotypes that are most suited to modulation of CRF systems for treatment (Zorrilla and Koob, 2010) . Finally, since women exhibit higher risk for stress-related anxiety disorders and preclinical evidence has shown significant sex biases in CRF signaling (Bangasser et al, 2013; Kessler et al, 1993; Weathington and Cooke, 2012) , we examined all behaviors in both males and females with comparative analysis between sexes.
MATERIALS AND METHODS

Generation of Mice with Inducible Forebrain-Specific CRF Overexpression
To achieve temporal control of CRF expression in the forebrain, we crossed two genetically modified mouse lines (backcrossed on C57BL/6J background to N48 generations) carrying a CaMKIIa promoter-driven rtTA2 transgene (Michalon et al, 2005) and a doxycycline-regulated tetO promoter fused to the CRF gene (Vicentini et al, 2009) to produce double mutant mice. Genotyping was carried out by quantitative polymerase chain reaction (Transnetyx, Memphis Tennessee, USA). CRFOE was induced by doxycycline (DOX) administration in either breeder chow for the dams (before weaning) or common mouse chow (after weaning) (Harlan Laboratories, Indianapolis, IN) in 6 mg DOX/g dose which corresponds to 3.5 mg DOX/g body weight/day. This dose was shown to induce a neuronspecific expression of different reporter genes in the forebrain with detectable levels after 4 days and reaching its maximum level after a week, and is able to induce CRFOE in the developing brain as early as P0 (Michalon et al, 2005) . DOX treatment was applied between postnatal day 2 (PD2) and PD23 (ie, prepubertal period) to induce CRFOE dev (n ¼ 11-16 per group), from PD2 to the end of testing to induce CRFOE life (n ¼ 7-12 per group), and from PD69 to the end of testing to induce CRFOE adult (n ¼ 18-21 per group). Testing started from PD90. After confirming that DOX alone did not affect behavioral outcomes in wildtype animals (Supplementary Table S1 ), double mutant littermates without DOX treatment were used as control subjects in all experiments.
Housing Conditions
Mice were housed 3-4/cage after weaning (PD28) in a temperature-controlled (21-22 1C) room under a reverse 12 h light/dark cycle (lights off at 0800 hours). All testing occurred from 1000 hours to 1400 hours and was conducted in accordance with the Principles of Laboratory Animal Care, National Institutes of Health guidelines, as approved by the University of California, San Diego Animal Care Committees.
Histological Verification of CRFOE
Immunohistochemistry. To characterize peptide levels at behavioral testing onset, a separate subset of CRFOE dev , CRFOE life , and CRFOE adult mice (N ¼ 5-6 per group) at PD90 were perfused and coronal brain sections were labeled for CRF using anti-CRF antibody (1 : 2000, Dr Wylie Vale, the Salk Institute, La Jolla, CA). See Supplementary Material for additional information.
In situ hybridization. To characterize the qualitative distribution of CRFOE during development, we assessed CRF RNA levels in separate subset of mice after 5, 12, and 21 days of DOX treatment and 2 weeks after cessation of DOX treatment (PD7, PD14, PD23, and PD37, respectively). In situ hybridization was performed using 35 S-UTP labeled riboprobes and analyzed as previously described (Flandreau et al, 2012) . See Supplementary Material for additional information.
Blood Sampling and Corticosterone Assay
Blood samples were collected from a subset of mice (N ¼ 5-15 per groups) between 7 and 10 am to assess baseline 'waking' corticosterone (CORT) levels in adulthood. Plasma corticosterone concentrations were measured by radioimmunoassay (MP Biomedicals, Solon, OH, USA). See Supplementary Material for additional information.
Experimental Design
Behavioral testing started at PD90 in the following order: locomotor/exploratory activity; conditioned fear; startle reactivity; and light/dark box with at least one week between tests. In all experiments, animals were placed in or adjacent to the testing room for habituation at least 1 h before testing.
Locomotor and Exploratory Activity Assessment
Locomotion and investigatory behavior were measured via photo-beam system in darkened activity chambers as previously described (San Diego Instruments, San Diego, CA, USA; (Risbrough et al, 2006a) ). Total distance moved (meters), rears, and hole pokes were recorded for 30 min. See Supplementary Material for additional information.
Conditioned Fear Test
Fear conditioning was assessed via an automatic photobeam procedure as previously described (Gresack et al, 2010) . Briefly, fear conditioning was induced by presentation of a tone (conditioned stimulus, CS: 75 dB, 4 kHz) for 20 s that co-terminated with a scrambled foot shock (unconditioned stimulus, US: 1 s, 0.5 mA). Three toneshock pairings were presented with an inter-trial interval of 40 s. Twenty-four hours later, subjects were re-exposed to the conditioning chamber and their freezing response was measured for 5 min during which time no shocks or tones were presented (context-dependent fear). Twenty-four hours afterwards mice were exposed again to the chambers with altered context across several dimensions (tactile, odor, visual) to minimize contextual cues and measure tone cue-induced fear. After a 5 min acclimation period, during which time no tones were presented ('pre-tone'), 12 tones were presented with an inter-trial interval of 5 s. See Supplementary Material for additional information.
Acoustic Startle
The procedure used here was adapted from previous studies (Risbrough et al, 2004) using startle chambers (San Diego Instruments) to test multiple domains of startle reactivity: baseline startle magnitude, prepulse inhibition (PPI), and habituation of startle.
Briefly, the acoustic startle sessions included four blocks. Sessions began with a 5-min acclimation period followed by delivery of five each of 120 dB startle pulses (Block1). Then a second block tested startle responses for different intensities (80, 90, 100, 110, and 120 dB). The third block tested PPI of 120 dB startle pulses using three different prepulse intensities (68, 71, and 77 dB). The last block included five pulses of 120 dB to assess startle habituation (% Reduction of Startle Magnitude ¼ Startle Magnitude (Block1) À Startle Magnitude (Block4)). In all experiments, the average startle magnitude over the record window (65 milliseconds) was used for all data analysis. See Supplementary Material for additional information.
Light/Dark Box Test
The light/dark box (LD box) consisted of two 18 Â 20 Â 18 cm chambers joined by a 6 Â 6 cm door. One side was well lit (850 lux) and the other was unlit/covered (o5 lux). Mice were placed in the light chamber at the start of the test and their activity was recorded for 5 min. Time spent in the dark chamber and number of entries into the light chamber were analyzed by Ethovision Tracking Software (Noldus, Leesburg, VA, USA).
Statistical Analysis and Data Visualization
All quantitative variables were analyzed by two-way ANOVA tests using Systat software (Systat, Chicago, IL, USA). Differences were considered significant and marginal if po0.05 and po0.10, respectively; higher p values are indicated as nonsignificant (ns). An effect of sex or interaction between sex and CRFOE was consistently present across tests, thus comparisons within each sex were completed for each test. When appropriate, post hoc comparisons were also conducted. Individuals were considered outliers and excluded from the analysis for a given task if they were out of the average±2.5 SD range, resulting in exclusion of: one male and one female control (no-DOX) subject from startle data analysis of CRFOE life cohort; one male control (no-DOX) subject from startle data analysis of CRFOE adult cohort; and one female CRFOE life (DOX-on) subject from LD box analysis.
RESULTS
Spatio-Temporal Overexpression of CRF
In situ hybridization showed robust CRFOE in forebrain regions that is largely reflective of expected CAMK2a expression patterns (Allen Mouse Brain Atlas, http:// mouse.brain-map.org/). Starting at PD14 and continuing to PD23, robust overexpression was detected in cortex, hippocampus, and striatum while limited in the hypothalamus. This overexpression was markedly reduced 14 days after the termination of DOX treatment (PD37) (Figure 1b) . Figure 1a and Table 1 show representative photomicrographs and summarize comparative CRF peptide levels in different brain regions across CRFOE groups at PD90. Double mutant mice without DOX treatment showed similar CRF immunoreactivity (ir) compared to C57BL/6J wild-type mice. Double mutants that had CRFOE in adulthood (CRFOE life and CRFOE adult ) showed different patterns of CRF-ir compared to CRFOE dev at the time of behavioral testing (PD90). In general, CRFOE in adulthood resulted in robust CRF-ir in basal ganglia-related structures (ie, striatum, ventral pallidum, and substantia nigra) with somewhat less dense CRF-ir in CRFOE adult than CRFOE life mice. CRFOE life mice exhibited prominent labeling in the hippocampus, lateral septum, and area surrounding the locus coeruleus (peri-LC) that was less apparent in CRFOE adult mice. In contrast, in CRFOE dev mice there was a notable absence of CRF-ir in most of the basal gangliarelated regions. Rather, these mice exhibited dense CRF-ir in the extended amygdala that was not seen in CRFOE adult or CRFOE life . In general, the distribution of CRF-ir in CRFOE dev mice was similar to control mice without DOX treatment but CRF-ir was more intense, whereas the actual pattern of CRF-ir differed in CRFOE adult and CRFOE life compared to CRFOE dev and controls. However, in situ hybridization in CRFOE dev mice during CRFOE-induction period showed an overexpression profile resembling the distribution found in CRFOE adult and CRFOE life groups (ie, in striatum and hippocampus). None of the CRFOE groups exhibited increased CRF-ir in the paraventricular nucleus of the hypothalamus. Of note, CRFOE dev mice exhibited a similar CRF-ir pattern to metallothionein promoter-driven CRFOE mice except the marked hypothalamic CRF-ir in the latter ( Figure 1a , Table 1 ; (Stenzel-Poore et al, 1994) ).
Weight and Corticosterone Levels
CRFOE life increased the body weight of female mice compared to controls, CRFOE dev and CRFOE adult female groups (po0.001; Supplementary Table S2 ). None of the other CRFOE groups showed a change in body weight compared to control subjects.
Females showed higher resting plasma corticosterone concentrations compared to males in all groups (F sex (1, 20) Basal ganglia Caudate
Abbreviations: BNST, bed nucleus of stria terminalis; MT-CRF, metallothionein promoter-driven CRFOE; peri-LC, adjacent region of the locus coruleus; VTA, ventral tegmental area; ( À ), no immunoreactivity; ( þ ), low immunoreactivity; ( þ þ ), moderate immunoreactivity; ( þ þ þ ), high immunoreactivity. Figure 1 Histological verification of CRFOE during and following CRFOE dev , CRFOE life , and CRFOE adult . (a) Representative photomicrographs displaying CRF immunoreactivity (white) at PD90 in selected coronal sections from 1.18 mm to À 5.40 mm relative to Bregma (Paxinos and Franklin, 2004) . Distinct patterns of CRF immunoreactivity are shown (from left to right) in wild-type C57BL/6J mice, metallothionein promoter-driven CRFOE mice (MT-CRF), controls (double mutant, DOX off) and double mutant mice exposed to CRFOE dev , CRFOE adult , and CRFOE life . (b) Transient CRFOE during development indicated by in situ hybridization. Upper and middle panels show sagittal brain sections of CRFOE dev and control/DOX off mice, respectively, on PD7, PD14, PD23, and PD37. CRFOE dev mice exhibited a gradual increase of CRFOE from PD7 to PD23, which was reversed close to control levels by PD37. Lower panels show Nissl-stained sagittal brain sections of CRFOE dev mice. BNST, bed nucleus of stria terminalis; CA3, field CA3 of the hippocampus; CeA, central amygdala; Cer, cerebellum; CPu, caudate putamen; Ctx, neocortex; DG, dentate gyrus; DR, dorsal raphe; EP, entopeduncular nucleus; Hip, hippocampus; Hyp, hypothalamus; GP, globus pallidus; IC, inferior colliculus; peri-LC, surrounding area of the locus coeruleus; LS, lateral septum; PO, preoptic area; PVN, paraventricular nucleus of the hypothalamus; SNC, substantia nigra, compact part; SNR, substantia nigra, reticular part; VP, ventral pallidum; VTA, ventral tegmental area.
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was not changed by CRFOE (absolute freezing levels: F crfoe o1, ns; elevation from pre-tone baseline: F crfoe o1.41, ns) (Supplementary Figure S1 ). Startle habituation was markedly diminished in both sexes following CRFOE dev . Male and female CRFOE life mice showed a similar trend, which was absent in CRFOE adult mice. (b) Prepulse inhibition of the startle response following CRFOE dev , CRFOE life , and CRFOE adult . CRFOE dev significantly reduced PPI in female mice whereas CRFOE life reduced PPI in both sexes with a more pronounced effect in males. In contrast, CRFOE adult had no effect on PPI. *po0.05, # po0.10 compared to same-sex control. Data are presented as mean±SEM. (Figure 3 ). In contrast, CRFOE adult mice did not exhibit differences in avoidance (F crfoe (1,41)o1, ns). Entries to the light compartment did not depend on CRFOE dev , CRFOE life or CRFOE adult exposure, suggesting locomotor activity in the chamber was unaffected by CRFOE (F crfoe o1, ns).
Acoustic Startle Response
DISCUSSION
Here we directly compared CRFOE in the forebrain during selective periods of the lifespan to model different possible CRF hypersignaling events on anxiety-like traits. We showed that CRFOE during prepubertal development, particularly in females, produced the strongest effects on anxiety-like behaviors with increased avoidance, diminished startle habituation and reduced PPI. Lifetime CRFOE induced similar behavioral trends suggesting that the impact of CRFOE in this group was mainly exerted during development, and hence, CRF hypersignaling during early life has enduring consequences on these anxiety-like traits. In contrast, CRFOE limited to adulthood had relatively mild and differential effects on anxiety-related phenotypes suggesting that anxiety-related phenotypic changes could depend on the timing of CRF hypersignaling across the lifespan. On the basis of these findings, developmental CRFOE may model some of the enduring anxiogenic effects of early-life stress, and have a significant role in heightened stress vulnerability in females. Although we found convergences between the phenotypic changes induced by CRFOE dev and CRFOE life , which are consistent with previous CRFOE models, our immunohistochemical analysis revealed marked differences of CRF-ir patterns between these models at the time of behavioral testing (PD90). CRFOE dev resulted in small increases in CRF levels predominantly in brain regions that endogenously express significant CRF and mediates anxiogenic effects of CRF (ie, extended amygdala) (Plotsky et al, 2005; Rainnie et al, 2004; Regev et al, 2012) . This expression profile is similar to expression profiles in mice with CRFOE controlled by the metallothionein promoter, with the exception of hypothalamic overexpression ( Figure 1a , Table 1 (Stenzel-Poore et al, 1994) ). In contrast, CRFOE life and CRFOE adult expression profile showed relatively normal CRF-ir labeling in the extended amygdala but strong labeling in the striatum and hippocampus, which have Figure 3 Avoidance behavior in the light-dark box following CRFOE dev , CRFOE life , and CRFOE adult . CRFOE dev and CRFOE life but not CRFOE adult increased avoidance in female mice as indicated by the time spent in the dark compartment. Avoidance behavior in male subjects was not affected by CRFOE. *po0.05 compared to same-sex control. Data are presented as mean±SEM.
lower CRF levels endogenously (Swanson et al, 1983) . Interestingly, CRF was recently found to exert anxiolytic actions in the globus pallidus and midbrain dopaminergic neurons in contrast to its major anxiogenic effects in the forebrain (Muller et al, 2003; Refojo et al, 2011; Sztainberg et al, 2011) . Lifetime CRFOE was also reported to induce significant CRF receptor expression changes in several forebrain areas including the cortex, septum, globus pallidus, and substantia nigra with additional reduction of urocortin expression (Korosi et al, 2006; Kozicz et al, 2004) . These findings may partially explain the different phenotypes between the CRFOE dev , CRFOE life , and CRFOE adult exposure models, with striatal CRF signaling possibly competing with the anxiogenic effects of CRF in other limbic regions. Since the present study focuses on the temporal comparison of CRFOE and lacks cell-type and region-specific manipulations of CRF expression, future studies are necessary to clarify this question. Importantly, during DOX administration period (PD2-23), we found that CRFOE dev mice showed a regional profile of CRFOE that mimicked CRFOE life and CRFOE adult groups at PD90, ie, high CRFOE in cortex, hippocampus, and striatum ( Figure 1b) . These data suggest that CRFOE was relatively uniform in distribution across these different exposure models during active DOX treatment. The similar behavioral consequences of CRFOE dev and CRFOE life that appear to be independent of acute CRF peptide levels at the time of testing suggest that increased avoidance and startle reactivity were due to developmental changes induced by early-life CRFOE.
Although the anxiogenic effects of acute CRF activation is well-documented (Adamec et al, 2010; Baldwin et al, 1991) , the present study with other CRFOE models can help to understand the specific spatio-temporal mechanisms of CRF in the development of heightened anxiety. First, CRFOE increased anxiety-like traits without affecting basal corticosterone concentrations, suggesting that CRF can exert anxiogenic effects independently from HPA-axis activation. These data are in line with other studies showing CRFR1 effects on anxiety that are independent of corticosterone or HPA CRF1 signaling (Muller et al, 2003; Smith et al, 1998; Timpl et al, 1998) . Second, these findings support the importance of early-life CRF hypersignaling in the development of heightened anxiety-like traits by showing increased anxiety in mice exposed to developmental CRFOE but not in mice exposed to adult-onset CRFOE. Consistently, embryonic-developmental (embryonic day 0 to PD21) or lifetime but not adult forebrainspecific CRFOE increased avoidance in most previous CRFOE models (Kolber et al, 2010; Stenzel-Poore et al, 1994; Vicentini et al, 2009) , but see (Groenink et al, 2003) . Several developmental studies have reported significant alterations in CRF activity in the forebrain following maternal separation and low maternal care as well as elevated CRF levels in the cerebrospinal fluid in these animals (Coplan et al, 1996; Ladd et al, 1996; Plotsky et al, 2005) . This latter finding is in line with human reports showing association between elevated cerebrospinal CRF concentration and childhood trauma history (Carpenter et al, 2004; Lee et al, 2005) . In addition, the CRF system shows intense maturation during early postnatal periods, eg, significant changes in CRFR1/R2 receptor expression (Avishai-Eliner et al, 1996) , thus early-life stress and CRF activation during this period can result in significant morphological and physiological changes in brain regions involved in stress-related behaviors (Ivy et al, 2010; Plotsky et al, 2005) . These findings may explain some potential mechanisms how early-life stress induces enduring changes in anxiety and psychological vulnerability (Kessler et al, 2010) .
CRFOE produced differential effects on startle reactivity by reducing habituation and PPI in mice exposed to developmental but not adult-onset overexpression. Only, male mice with adult-onset CRFOE exhibited increased startle magnitude which is consistent with acute CRF treatment effects (Risbrough et al, 2003) . These findings suggest that exposure of the developing brain to CRF hypersignaling leads to marked changes of startle plasticity and sensorimotor gating. In humans, there is only indirect evidence for an association between PPI disruption and early-life stress, with some anxiety disorders with poor startle habituation and PPI deficits also being associated with early-life stressors (Braff et al, 2001; Ludewig et al, 2005) . Future clinical research is needed to confirm if early-life stress is specifically associated with poor sensorimotor gating. Mechanisms for the developmental effect of CRFOE on PPI are currently unclear, however, lifetime CRFOE mice showed recovery of PPI after acute CRFR1 receptor antagonist treatments, inferring that the PPI deficits are due to CRFR1 hypersignaling (Groenink et al, 2008) . Interestingly, the impact of CRFOE on fear conditioning revealed an opposite effect of exposure period on behavior compared to startle behaviors. Although acute CRF administration has been shown to enhance fear acquisition (Hubbard et al, 2007; Radulovic et al, 1999) , adult-onset CRFOE reduced context-dependent freezing in females but left conditioned fear unaffected following prepubertal or lifetime exposure. Previous models of lifetime CRFOE similarly showed either no effect or reduced conditioned fear learning (Groenink et al, 2003) . Thus chronic CRF hypersignaling in adulthood affects contextual freezing differently than acute manipulations, suggesting neuroadaption in CRF signaling pathways that affect learned fear (Silberstein et al, 2009 ). 
Most of the observed behavioral effects of CRFOE were present or more pronounced in females (for a summary, see Table 2 ). Given the very robust overexpression of the transgene (Figure 1a and b) , we do not expect that the behavioral sex differences are due to differences in expression of the CRF transgene itself, but are instead due to sex differences in the endogenous CRF signaling pathways in response to high CRF since females exhibit altered cellular responses to CRF signaling (Bangasser et al, 2013) . Locus coeruleus neurons of female rats are more sensitive to CRF resulting in heightened noradrenergic reactivity during stress or in conditions of CRF overexpression, likely due to their limited ability to desensitize CRFR1 receptors (Bangasser et al, 2010; Bangasser et al, 2013; Curtis et al, 2006) . This mechanism may partly explain why women show higher incidence of stress-related affective and anxiety disorders compared to men and why CRFOE appeared to result in more behavioral changes in females compared to males (Koenen and Widom, 2009 ).
There are a number of limitations to this study that should be noted. The forebrain CRFOE pattern that was induced by the CAMK2a promoter induced ectopic CRF expression in areas with relatively low CRF receptor abundance (eg, striatum). The phenotypes were relatively similar across CRFOE dev and CRFOE life , despite relatively large differences in peptide distribution and level at the time of testing, which may suggest that the behavioral effects were driven by CRF signaling in a limited shared circuit. In addition, we cannot exclude the possibility that the differences in phenotype between adult exposure and the other groups could be at least partially accounted for differences in delays between behavioral testing and induction of CRFOE. Further study is warranted to examine if these behavioral phenotypes are altered across differential time periods after CRFOE is initiated and to identify when, after development, the effects of prepubertal CRFOE emerge. Overall, the present study provides evidence for a causal role of early-life CRF hypersignaling in the development of specific 'symptom domains' related to anxiety disorders in adulthood. The fact that forebrain CRFOE during early development could account for all of the effects of CRFOE across the lifespan suggests that forebrain CRFOE in development has relatively strong consequences on adult anxiety-like traits. Finally, the overall finding that females were more responsive to CRFOE across the different exposure groups supports the hypothesis that females may exhibit differential sensitivity to CRF signaling compared to males.
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